The UK Kidney Association (UKKA) endorses the use of generic dapagliflozin for patients with Chronic Kidney Disease (CKD), consistent with NICE guidelines. There is robust evidence that SGLT2 inhibitors have a class effect and have demonstrated clear efficacy, including reducing the risk of end-stage kidney disease and cardiovascular event risk. Therefore, switching from branded SGLT2i's to generic dapagliflozin is most likely to preserve treatment effectiveness, safety and will facilitate broader patient access to them. Clinicians are advised to follow local guidelines regarding switching protocols and to ensure ongoing monitoring according to national clinical guidance. There is no indication for additional testing for either eGFR and/or urine ACR when making the switch to generic dapagliflozin.